Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway

Journal of Cardiovascular Translational Research

Volumn 6, Issue 5, 2013, Pages 826-833

  Lanfear, David E ^a,b   Sunkara, Bipin ^a   Li, Jia ^b   Rastogi, Sharad ^a   Gupta, Ramesh C ^a   Padhukasahasram, Badri ^b   Williams, L Keoki ^b   Sabbah, Hani N ^a  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Gene expression; Genetic polymorphisms; Heart failure; Natriuretic peptide; Nesiritide; Pharmacogenomics

Indexed keywords

NATRIURETIC FACTOR;

ARTICLE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HUMAN; NPR2 GENE; PHARMACOGENOMICS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC MARKERS; HUMANS; KIDNEY; LINEAR MODELS; NEPRILYSIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA;

EID: 84885577881     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9491-y     Document Type: Article

References (26)

1. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., Lisabeth, L. D., Makuc, D. M., Marcus, G. M., Marelli, A., Matchar, D. B., Moy, C. S., Mozaffarian, D., Mussolino, M. E., Nichol, G., Paynter, N. P., Soliman, E. Z., Sorlie, P. D., Sotoodehnia, N., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D., & Turner, M. B. (2012). Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation, 125(1), e2-e220. doi: 10.1161/CIR.0b013e31823ac046.
2. Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T., & Kinoshita, M. (1998). Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 135(5 Pt 1), 825-832.
3. Ellmers, L. J., Scott, N. J., Piuhola, J., Maeda, N., Smithies, O., Frampton, C. M., Richards, A. M., & Cameron, V. A. (2007). Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol, 38(1-2), 245-257. doi: 10.1677/jme.1.02138.
4. Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H., Clopton, P., Steg, P. G., Westheim, A., Knudsen, C. W., Perez, A., Kazanegra, R., Herrmann, H. C., & McCullough, P. A. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 347(3), 161-167. doi: 10.1056/NEJMoa020233.
5. Pascual-Figal, D. A., Domingo, M., Casas, T., Gich, I., Ordonez-Llanos, J., Martinez, P., Cinca, J., Valdes, M., Januzzi, J. L., & Bayes-Genis, A. (2008). Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J, 29(8), 1011-1018. doi: 10.1093/eurheartj/ehn023.
6. VMAC Investigators (Vasodilation in the Management of Acute CHF). (2002). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 287(12), 1531-1540.
7. Colucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C. S., Neibaur, M., Haught, W. H., & LeJemtel, T. H. (2000). Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med, 343(4), 246-253. doi: 10.1056/nejm200007273430403.
8. Maisel, A. S., Clopton, P., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H., Steg, G., Westheim, A., Knudsen, C. W., Perez, A., Kazanegra, R., Bhalla, V., Herrmann, H. C., Aumont, M. C., & McCullough, P. A. (2004). Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J, 147(6), 1078-1084. doi: 10.1016/j.ahj.2004.01.013.
9. Costello-Boerrigter, L. C., Boerrigter, G., Ameenuddin, S., Mahoney, D. W., Slusser, J. P., Heublein, D. M., Redfield, M. M., Rodeheffer, R. J., Olson, T. M., & Burnett, J. C., Jr. (2011). The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc, 86(3), 210-218. doi: 10.4065/mcp.2010.0708.
10. O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G. M., Komajda, M., Massie, B. M., McMurray, J. J., Nieminen, M. S., Reist, C. J., Rouleau, J. L., Swedberg, K., Adams, K. F., Jr., Anker, S. D., Atar, D., Battler, A., Botero, R., Bohidar, N. R., Butler, J., Clausell, N., Corbalan, R., Costanzo, M. R., Dahlstrom, U., Deckelbaum, L. I., Diaz, R., Dunlap, M. E., Ezekowitz, J. A., Feldman, D., Felker, G. M., Fonarow, G. C., Gennevois, D., Gottlieb, S. S., Hill, J. A., Hollander, J. E., Howlett, J. G., Hudson, M. P., Kociol, R. D., Krum, H., Laucevicius, A., Levy, W. C., Mendez, G. F., Metra, M., Mittal, S., Oh, B. H., Pereira, N. L., Ponikowski, P., Tang, W. H., Tanomsup, S., Teerlink, J. R., Triposkiadis, F., Troughton, R. W., Voors, A. A., Whellan, D. J., Zannad, F., & Califf, R. M. (2011). Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med, 365(1), 32-43. doi: 10.1056/NEJMoa1100171.
11. Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K. (2005). Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA, 293(15), 1900-1905. doi: 10.1001/jama.293.15.1900.
12. Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005). Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 111(12), 1487-1491. doi: 10.1161/01.cir.0000159340.93220.e4.
13. Luss, H., Mitrovic, V., Seferovic, P. M., Simeunovic, D., Ristic, A. D., Moiseyev, V. S., Forssmann, W. G., Hamdy, A. M., & Meyer, M. (2008). Renal effects of ularitide in patients with decompensated heart failure. Am Heart J, 155(6), 1012.e1011-1018. doi: 10.1016/j.ahj.2008.02.011.
14. McKie, P. M., Sangaralingham, S. J., & Burnett, J. C., Jr. (2010). CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep, 7(3), 93-99. doi: 10.1007/s11897-010-0016-6.
15. Lanfear, D. E. (2010). Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev, 15(3), 219-228. doi: 10.1007/s10741-008-9113-y.
16. Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Corey, D., Leip, E. P., & Vasan, R. S. (2003). Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation, 108(1), 13-16. doi: 10.1161/01.cir.0000081657.83724.a7.
17. Newton-Cheh, C., Larson, M. G., Vasan, R. S., Levy, D., Bloch, K. D., Surti, A., Guiducci, C., Kathiresan, S., Benjamin, E. J., Struck, J., Morgenthaler, N. G., Bergmann, A., Blankenberg, S., Kee, F., Nilsson, P., Yin, X., Peltonen, L., Vartiainen, E., Salomaa, V., Hirschhorn, J. N., Melander, O., & Wang, T. J. (2009). Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet, 41(3), 348-353. doi: 10.1038/ng.328.
18. Lanfear, D. E., Stolker, J. M., Marsh, S., Rich, M. W., & McLeod, H. L. (2007). Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther, 21(1), 55-62. doi: 10.1007/s10557-007-6007-5.
19. Lanfear, D. E., Stolker, J. M., Marsh, S., Rich, M. W., & McLeod, H. L. (2006). Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. Therapy, 3(6), 765-771. doi: 10.2217/14750708.3.6.765.
20. Lanfear, D. E., Yang, J., Leszczynski, K., & Sabbah, H. N. (2011). Natriuretic peptide receptor 3 genotype is associated with altered pharmacokinetics during nesiritide infusion. J Card Fail, 17(8), S62.
21. Gauderman, W. J., Murcray, C., Gilliland, F., & Conti, D. V. (2007). Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol, 31(5), 383-395. doi: 10.1002/gepi.20219.
22. Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet, 38(8), 904-909.
23. An, P., Mukherjee, O., Chanda, P., Yao, L., Engelman, C. D., Huang, C. H., Zheng, T., Kovac, I. P., Dube, M. P., Liang, X., Li, J., de Andrade, M., Culverhouse, R., Malzahn, D., Manning, A. K., Clarke, G. M., Jung, J., & Province, M. A. (2009). The challenge of detecting epistasis (G x G interactions): Genetic Analysis Workshop 16. Genet Epidemiol, 33(Suppl 1), S58-67. doi: 10.1002/gepi.20474.
24. Oh, S., & Park, T. (2007). Association tests based on the principal-component analysis. BMC Proc, 1(Suppl 1), S130.
25. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001). Controlling the false discovery rate in behavior genetics research. Behav Brain Res, 125(1-2), 279-284.
26. Vogel, C., & Marcotte, E. M. (2012). Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet, 13(4), 227-232. doi: 10.1038/nrg3185.